Celgene logo Celgene Logo
Search

  • Australia
    • Australia
      • English
    • Austria
      • Deutsch
    • Belgium
      • Français
      • Nederlands
    • Brazil
      • Português
    • Canada
      • English
      • Français
    • Czech Republic
      • Čeština
    • Denmark
      • Dansk
    • Europe
      • English
    • Finland
      • Suomi
    • France
      • Français
    • Germany
      • Deutsch
    • Ireland
      • English
    • Italy
      • Italiano
    • Japan
      • 日本語
    • Luxembourg
      • Français
      • Nederlands
    • Mexico
      • Español
    • Netherlands
      • Nederlands
    • Norway
      • Norsk
    • Poland
      • Polski
    • Portugal
      • Português
    • Russia
      • Русский язык
    • South Korea
      • 한국어
    • Spain
      • Español
    • Sweden
      • Svenska
    • Switzerland
      • Deutsch
      • Français
    • Turkey
      • Türk
    • United Kingdom
      • English
    • United States
      • English
  • About
    • Compliance
    • History
    • Global Office Locations
  • Product Information
    • Patient Safety
    • Anti-counterfeiting
  • Research & Development
    • Pipeline
    • Medical Innovation
      • IMiDs
    • R&D Locations
    • Clinical Trials
      • Celgene-sponsored Trials
      • Investigator-initiated Trials
    • Celgene Medical Affairs
  • Responsibility
    • Patients & Communities
    • Medicines Australia & Transparency
    • Commitment to Safety
    • Global Health
  • Media
  • Patients
    • Glossary
    • Online Patient Resources
  • Healthcare Professionals
  • Investors
  • Careers
  • Contact Us
  • Home
  • 12
  • Data Presented on REVLIMID® (lenalidomide) Compared with Investigators' Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Font Size Smaller Font Size Larger Font Size

Data Presented on REVLIMID® (lenalidomide) Compared with Investigators' Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

09.12.2014

Data Presented on REVLIMID® (lenalidomide) Compared with Investigators' Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Media

Search News

Most Read

  • A Decade of Progress in Myeloma, And More to Come

  • Creating an Innovative Biopharma Leader with Global Reach and Scale

  • Myeloma Was Not the End of My Story


Global Office Locations

world map

HAVE A QUESTION OR CONCERN?
CONTACT US

  • About
  • Product Information
  • Research & Development
  • Responsibility
  • Media
  • Patients
  • Healthcare Professionals
  • Investors
  • Careers
  • Pipeline
  • Privacy Policy
  • Legal Notice
  • Site Map
  • Copyright © 2021 Celgene Corporation
    A Bristol Myers Squibb Company
  • Privacy
    Policy
  • Legal
    Notice
  • Media
X

You are now leaving www.celgene.com.au, a website provided by Celgene Pty Limited. The information you are about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the company or via the Product Information tab. This link will take you to a website to which this  Privacy Policy does not apply. Celgene Pty Limited does not endorse and/or influence the content found on this website, including those from Celgene Corporation (U.S.) and other Celgene country affiliates. You are solely responsible for your interactions with this website.​

Continue

To leave the Celgene Australia site

Cancel

To return to https://www.celgene.com.au​

These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than the U.S., please contact the local office (as listed under the Global Network).

Continue

To view

Cancel

To return to www.Celgene.com

Celgene is a Bristol Myers Squibb company


Select CONTINUE for information about Celgene.

Select BMS to learn more about Bristol Myers Squibb.



CONTINUE BMS